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HypofractionationBackground and purpose: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast
radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two
acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to
early skin reactions.
Material and methods: Patients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/
1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and
CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended.
Primary endpoint was the proportion of patients within each treatment group with grade P3 toxicity
(RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.
Results: 190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG
toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second sub-
study, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%);
26 Gy/5F 0/53.
Conclusions: Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under
test in FAST-Forward were mild.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 120 (2016) 114–118
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).FAST-Forward is a randomised, multi-centre, three-group,
non-blind, phase 3 clinical trial addressing the hypothesis that a
1-week course of adjuvant whole breast radiotherapy is at least
as effective and safe as the UK standard 3-week regimen after pri-
mary surgery for early breast cancer. The primary endpoint for the
main trial is local recurrence; Acute and late radiotherapy related
adverse events are important secondary endpoints. Acute skin
reactions are less sensitive to fraction size than late reacting nor-
mal tissues, so the lower total doses under test in the trial are
expected to reduce their severity and duration, despite the shorter
overall treatment time. In order to confirm these relationships, two
acute toxicity substudies were undertaken during 2011 and 2013in patients entered into the main trial. The need for two cohorts
related mainly to a suboptimal choice of scoring system for the
first substudy (described in Results). The results of both first and
second toxicity substudies are presented here.Materials and methods
Participants and treatment
In the main study, patients were allocated in a 1:1:1 ratio to
40 Gy/15F/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week.
Randomisation used computer generated random permuted blocks
stratified by radiotherapy centre and tumour risk group. Centres
telephoned The Institute of Cancer Research Clinical Trials and
Statistics Unit randomisation service to ascertain the allocated
treatment. Inclusion and exclusion criteria to the first and second
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protocol (http://public.ukcrn.org.uk/Search/StudyDetail.aspx?
StudyID=10896), including patients who had undergone either
breast conservation surgery or mastectomy (both substudies), with
or without axillary dissection and/or cytotoxic therapies, and
excluding patients requiring radiotherapy to regional lymph nodes
other than lower axilla in standard tangential fields to breast/chest
wall. Patients requiring a radiotherapy tumour bed boost dose
were eligible for the first substudy, but were excluded from the
second substudy in order to restrict the comparisons to the
whole-breast component of treatment. At centres participating in
the substudies, consecutive eligible patients were invited to partic-
ipate at the time of consent to the main trial.
All patients provided written informed consent. FAST-Forward
was approved by the national South East Coast Kent Research
Ethics Committee (11/LO/0958) and the local Research andTable 1
Radiotherapy details of patients in first and second acute toxicity substudies.
Radiotherapy (RT) details Acute toxicity substudy 1
40 Gy/15F 27 Gy/5F
N = 64a N = 62
N (%) N (%)
Radiotherapy received
Yes 64 (100) 62 (100)
No 0 1 (2)c
Boost received
Yes 11 (17) 11 (18)
No 53 (83) 51 (82)
Treatment duration in patients receiving no boost (including weekends and bank holiday
Median (IQR) 22 (21–23) 5 (5–7)
Range 1–25 5–11
Treatment duration in patients receiving boost (including weekends and bank holidays)
Median (IQR) 30 (26–33) 18 (12–20)
Range 22–35 7–20
Whole breast – total fractions
5 0 62 (100)
15 63 (98) 0
Otherf 1 (2) 0
Whole breast – total dose (Gy)
26 0 0
27 0 62 (100)
40 63 (98) 0
Other6 1 (2) 0
Bolus used (mastectomy patients only)
Yes 1 (100) 1 (33)
No 0 2 (67)
Dose homogeneity constraints achieved
Yes 62 (97) 61 (98)
No 2 (3) 1 (2)
Organs at risk dose constraints achieved
Yes 64 (100) 61 (98)
No 0 1 (2)
Any deviations from RT
Yes 1 (2) 0
No 63 (98) 62 (100)
Whole breast RT extended by >3 days
Yes 0 0
No 64 (100) 62 (100)
a Includes one patient randomised to receive 26 Gy/5F who was treated with 40 Gy/15F
analyses.
b Includes one patient randomised to receive 26 Gy/5F who was treated with 40 G
subsequent analyses.
c Patient refused any radiotherapy after randomisation.
d Patient withdrew consent prior to radiotherapy.
e Treatment duration for 40 Gy/15F patients with no boost is 19 days if it starts on a Mo
5 days treatment if it starts on a Monday and 7 days if it starts Tuesday to Friday.
f One patient randomised to 40 Gy/15F who chose to discontinue radiotherapy after rDevelopment offices of all participating centres. The trial was
sponsored by The Institute of Cancer Research and undertaken in
accordance with the principles of Good Clinical Practice. This study
is registered as an International Standard Randomised Controlled
Trial, number ISRCTN19906132.
All patients underwent 3D CT-based treatment planning,
including outlining of breast/chest wall to define clinical target vol-
ume and planning target volume (PTV) encompassed by medial
and lateral tangential beams using megavoltage X-rays. The treat-
ment plan was prescribed to a clinically relevant reference point
and was optimised with 3D dose compensation to ensure >95%
PTV received 95%, <5% PTV received P105%, <2% PTV received
P107% and a global Dmax <110% of prescribed dose. Dose con-
straints for organs at risk were also specified in the protocol. Beam
energies were usually 6 MV, but a mixture of higher energies could
be used for large patients. Centres applying post-mastectomy bolusAcute toxicity substudy 2
26 Gy/5F 40 Gy/15F 27 Gy/5F 26 Gy/5F
N = 63 N = 55b N = 44 N = 61
N (%) N (%) N (%) N (%)
63 (100) 54 (98) 44 (100) 61 (100)
0 1 (2)d 0 0
7 (11) 0 0 0
56 (89) 54 (100) 44 (100) 61 (100)
s)e
7 (5–7) 21 (20–22) 6 (5–7) 6 (5–7)
1–9 15–23 5-8 5-8
14 (12–17) – – –
7–21 – – –
63 (100) 0 44 (100) 61 (100)
0 54 (100) 0 0
0 0 0 0
63 (100) 0 0 61 (100)
0 0 44 (100) 0
0 54 (100) 0 0
0 0 0 0
3 (50) 2 (40) 1 (50) 5 (100)
3 (50) 3 (60) 1 (50) 0
60 (95) 53 (98) 44 (100) 60 (98)
3 (5) 1 (2) 0 1 (2)
62 (98) 53 (98) 44 (100) 61 (100)
1 (2) 1 (2) 0 0
0 1 (2) 0 0
63 (100) 53 (98) 44 (100) 61 (100)
0 0 0 0
63 (100) 54 (100) 44 (100) 61 (100)
due to patient choice, this patient is included in 40 Gy/15F group for all subsequent
y/15F due to coverage issues, this patient is included in 40 Gy/15F group for all
nday and 21 days if it starts Tuesday to Friday. 27 Gy/5F and 26 Gy/5F patients have
eceiving 32 Gy/12F.
116 Acute toxicity in the UK FAST-Forward Trialto the skin had to specify this intention prior to randomisation,
including whether it was applied to whole skin or scar, for whole
treatment or part there-of and the intended thickness. Treatment
verification included daily portal imaging in patients randomised
to 5-fraction schedules and imaging on the first three fractions
and then weekly for patients randomised to 40 Gy/15F.Assessments
Acute reactions of the skin of the treated breast were graded
using RTOG criteria for the first substudy. Following discussions
with both the FAST-Forward Independent Data Monitoring Com-
mittee and Trial Steering Committee, it was agreed that this may
not be the most appropriate scoring system in this context due
to the inclusion of oedema in the RTOG system, since the primary
concern was to score moist desquamation. Therefore it was agreed
that a second substudy would be undertaken using standard CTCAE
criteria (v4.03) (Appendix 3). Toxicity assessments were made by a
healthcare professional at each participating centre using pre-
designed forms, see Appendix 4. The assessments were scheduled
to be carried out weekly during treatment and for 4 weeks follow-
ing the end of radiotherapy. In the second substudy, if moist
desquamation beyond skin folds or creases (CTCAE grade 3) were
seen during this time, weekly assessments were to continue until
the reaction resolved to CTCAE grade 1 or less. If any assessment
was missed, the centre contacted the patient by telephone to
assess and grade (by asking the patient to describe the skin appear-
ance and supplementing this by direct questions) acute skin reac-
tions using a missed assessment form, see Appendix 5.Statistical considerations
The primary endpoint for each of the substudies was the pro-
portion of patients within each treatment group with grade P3
toxicity (RTOG and CTCAE respectively) at any time from the start
of radiotherapy to 4 weeks after completion of radiotherapy. The
secondary endpoints were clinical assessment of (i) any acute skin
toxicity, defined as the worst grade reported from the start of
radiotherapy to 4 weeks post-radiotherapy, (ii) acute skin toxicity
during radiotherapy, defined as the worst grade reported from
the start to the end of radiotherapy, (iii) acute skin toxicity post
radiotherapy, defined as the worst grade reported at completion
of radiotherapy until at least 4 weeks post radiotherapy and (iv)
adherence to the acute toxicity assessments
Principal analyses were based on the evaluable population,
defined as all patients randomised into the study receiving at leastTable 2
Overall compliance to toxicity assessments during and post radiotherapy.
Total number of acute toxicity assessments
during and post treatment
Acute toxicity substudy 1
40 Gy/15F 27 Gy/5F
N = 64 N = 62
N (%) N (%)
Expected number of assessments 7 5
Number of completed assessmentsa
0 2 (3) 0
1 3 (5) 3 (5)
2 2 (3) 3 (5)
3 5 (8) 5 (8)
4 1 (2) 16 (26)
5 7 (11) 35 (56)
6 14 (22) –
7b 30 (47) –
Total number evaluable 44 51
a Only includes non-boost assessments (First substudy).
b Includes one patient with 4 on-treatment assessments +4 post-treatment assessmenone fraction of radiotherapy (regardless of whether they were later
found to be ineligible or a protocol violator) andwith complete data,
or, at most, one missing toxicity assessment. For the first substudy
which included some patients receiving a boost, only non-boost
assessments were used to define inclusion in the evaluable popula-
tion. The required number of assessments for a 40 Gy/15F patient
was 7 (3 during and 4 post-radiotherapy) and 5 for 27 Gy/5F and
26 Gy/5F patients (1 during and 4 post-radiotherapy). Patients
who switched to receive a different trial treatment after randomisa-
tionwere analysed according to treatment received rather than ran-
domised treatment. For the primary endpoint, the proportion of
patients within each treatment group with gradeP3 RTOG toxicity
(first substudy) or gradeP3 CTCAE (second substudy) toxicity was
estimatedwith associated upper one-sided 95% confidence interval.
Secondary endpoints were estimated as frequencies and percent-
ages, with the prevalence of gradesP1,P2 andP3 toxicity at each
time-point presented graphically. Adherence to toxicity assess-
ments was estimated as frequencies and percentages. Toxicity data
were included as reported, there were no restrictions based on the
date of assessment. The acute toxicity substudy was designed to
be non-comparative so no statistical comparisonsweremade across
the treatment groups.
Each substudy aimed to recruit approximately 150 evaluable
patients (50 per group) in order to exclude a within-group rate
of grade P3 acute skin reactions of over 11% compared to target
rate of under 3% (89% power and one-sided 7.9% significance level).
Results
Recruitment to the first acute toxicity substudy opened in
November 2011 and closed in May 2012. Of 194 potentially eligible
patients recruited in substudy centres, 190 patients consented (63,
63 and 64 in the 40 Gy/15F, 27 Gy/5F and 26 Gy/5F groups, respec-
tively). Recruitment was performed at 9 treating centres across the
UK with the infrastructure to carry out weekly toxicity
assessments.
Recruitment to the second acute toxicity substudy opened in
April 2013 and closed in February 2014. Of 269 potentially eligible
patients recruited in the 8 substudy centres, 162 patients con-
sented (55, 44 and 63 in the 40 Gy/15F, 27 Gy/5F and 26 Gy/5F
groups, respectively). Two patients subsequently withdrew con-
sent for all data to be used. The number of patients potentially eli-
gible, consented, receiving allocated radiotherapy and evaluable
for the primary endpoint for each substudy is given in Appendix 1.
Baseline characteristics are presented for all consenting
patients recruited to the substudy, and were broadly comparableAcute toxicity substudy 2
26 Gy/5F 40 Gy/15F 27 Gy/5F 26 Gy/5F
N = 63 N = 55 N = 44 N = 61
N (%) N (%) N (%) N (%)
5 7 5 5
1 (2) 6 (11) 0 1 (2)
4 (6) 0 0 1 (2)
0 0 1 (2) 1 (2)
6 (10) 1 (2) 2 (5) 5 (8)
14 (22) 1 (2) 5 (11) 7 (11)
38 (60) 4 (7) 36 (82) 46 (75)
– 9 (16) – –
– 34 (62) – –
52 43 41 53
ts.
Fig. 1. Acute toxicity substudy 2 – Prevalence of grade 1+, grade 2+ and grade 3+
CTCAE toxicity.
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in numbers allocated to different groups are within expectation of
random variation. Treatment characteristics and comorbidity data
were comparable to those collected from all patients in the main
trial, and there were no obvious imbalances in features between
toxicity study groups (data not shown).
Radiotherapy treatment characteristics (for each substudy sep-
arately) are presented in Table 1, suggesting no significant imbal-
ances between groups. Compliance to toxicity assessments by
treatment group is shown in Table 2. For the first acute toxicity
substudy, worst RTOG grade experienced by treatment received
is reported in Table 3a. The proportions of evaluable patients with
grade 3 RTOG toxicity during the acute phase were as follows:
40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52
(5.8%). Twenty-nine patients in the first substudy received a boost
to their treatment, of which 22 were evaluable. No evidence of a
higher rate of grade 3 toxicity was observed in this subset of
patients (40 Gy/15F 1/9 (11.1%); 27 Gy/5F 0/10; 26 Gy/5F 0/3).Table 3a
Acute skin toxicities reported. Acute toxicity substudy 1 – Worst acute CTCAE score
according to treatment.
Worst RTOG grade
(on or post RT)
40 Gy/15F 27 Gy/5F 26 Gy/5F
N = 44 N = 51 N = 52
N (%)a N (%)a N (%)a
0 0 2 (4) 3 (6)
1 14 (32) 24 (47) 32 (62)
2 24 (55) 20 (39) 14 (27)
3 6 (14) 5 (10) 3 (6)
4 0 0 0
Percentage of RTOG grade 3+
(upper limit of one-sided 95% CI)
13.6
(25.2)%
9.8
(19.5%)
5.8
(14.2)%
a Percentages calculated from those evaluable.
Table 3b
Acute toxicity substudy 2 – Worst acute CTCAE score according to treatment.
CTCAE grade 40 Gy/15F 27 Gy/5F 26 Gy/5F
N = 43 N = 41 N = 53
N (%)a N (%)a N (%)a
0 0 3 (7) 3 (6)
1 21 (49) 26 (63) 31 (58)
2 22 (51) 11 (27) 19 (36)
3 0 1 (2)b 0
4 0 0 0
Proportion grade 3+
(upper limit of one-sided 95% CI)
0 (6.7)% 2.4 (11.1)% 0 (5.5)%
a Percentages calculated from those evaluable.
b Grade 3 toxicity reported at 4 weeks post-RT resolved to grade 1 one week later.
Table 3c
Acute toxicity substudy 2 – Nature of grade 1 and 2 toxicities according to treatment.
CTCAE grade 1 and 2 symptoms 40 Gy/15F 27 Gy/5F 26 Gy/5F
N (%)a N (%)a N (%)a
Grade 1
Faint erythema 42 (98) 38 (93) 47 (89)
Dry desquamation 7 (16) 1 (2) 8 (15)
Grade 2
Moderate to brisk erythema 20 (47) 11 (27) 16 (30)
Patchy moist desquamation
confined to skin folds/creases
8 (19) 2 (5) 6 (11)
Moderate oedema 2 (5) 0 1 (2)
a Percentages calculated from those evaluable.For the second acute toxicity substudy, worst CTCAE grade expe-
rienced by treatment received is reported in Table 3b. The propor-
tions of evaluable patients with a grade 3 CTCAE toxicity during the
acute phase were as follows: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%);
26 Gy/5F 0/53. Grade 2 toxicitywas largely due tomoderate to brisk
erythema, with only 3 patients with moderate oedema (two
40 Gy/15F and one 26 Gy/5F patient), see Table 3c. CTCAE toxicity
score reported at each time point is presented graphically during
radiotherapy and post radiotherapy, see Fig. 1. A single patient in
the second cohort randomised to the 27 Gy/5F group after mastec-
tomy, adjuvant cytotoxic chemotherapy and chest wall radiother-
apy with bolus was assessed as a CTCAE grade 3 toxicity recorded
after a missed assessment by telephone appointment 36 days after
start of treatment, having been assessed as grade 2 seven days
before and assessed with grade 1 erythema seven days later.
Discussion
The acute skin toxicity substudies were not designed to involve
statistical hypothesis testing across treatment groups, but to con-
firm low incidence rates of clinically significant acute skin toxicity
associated with each schedule. On this basis, the results raise no
concerns that the 5-day schedules lead to more severe or longer-
lasting acute skin reactions compared to 40 Gy in 15 fractions.
The prevalence rates summarised in Fig. 1 suggest that erythema
after the 1-week schedule is less intense and settles about 2 weeks
earlier than after the 3-week schedule. An imbalance in numbers in
the 27 Gy group is attributed to the play of chance, since consent to
participate in the substudy was obtained prior to allocation of ran-
domised treatment. Overall compliance with the toxicity assess-
ments was high, making it unlikely that patients developing
severe skin reactions were under-reported. No suggestion of a dose
response is noted between the 2 dose levels of the 5-fraction test
regimens. The results of the first toxicity substudy are consistent
with those from the second substudy, despite the unhelpful
inclusion of oedema with erythema and desquamation in the RTOG
system used for scoring early skin reactions.
The mildness of the acute skin toxicity associated with the
5-fraction regimens was expected. A series of classic studies
investigating the dependence of acute skin reactions on total dose,
fraction size, inter-fraction interval and overall treatment time was
undertaken in the 1980 s and 1990 s by Turesson and colleagues,
using reflectance spectrophotometry to quantify erythema and
clinical grading to score moist desquamation [1–3]. These con-
firmed the absence of a treatment time effect for the first 4 weeks
of radiotherapy delivered using fraction sizes of 2.0 Gy and 4.0 Gy
118 Acute toxicity in the UK FAST-Forward Trialdelivered using 12 MeV electrons to the internal mammary chain
daily or twice per week [1]. Using the same experimental system,
whereby different fractionation regimens were delivered to right
and left internal mammary chains of the same patient, weak
dependence of erythema and desquamation on fraction size was
demonstrated, with estimates of a/b ratios between 7.5 and
11.2 Gy [2]. In the context of the FAST-Forward trial, the reductions
in total dose, from 40 Gy to 27 Gy and 26 Gy appear to compensate
for increased dose per fraction where acute skin reactions are con-
cerned. In conclusion, the acute skin toxicity substudies conducted
in patients entered into the FAST-Forward trial raise no concerns,
while long-term outcomes on the total trial population of 4000
patients are awaited.
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